Skip to content
BiologicalX

Comparison

Omega-3 (EPA/DHA) vs Spermidine

Side-by-side of Omega-3 (EPA/DHA) and Spermidine. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Omega-3 (EPA/DHA)

  • Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
  • REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
  • Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
  • Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
  • Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
  • Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state

Spermidine

  • Endogenous polyamine that induces autophagy via EP300 acetyltransferase inhibition and TFEB activation
  • Concentrated in wheat germ, soybeans, aged cheese, and mushrooms; ~10 to 15 mg/day in Mediterranean diets
  • Eisenberg 2016 reported dietary spermidine extended mouse lifespan and improved cardiac function
  • Wirth 2018 pilot (n=28) reported cognitive signal at 0.9 mg/day in older adults at risk for dementia
  • Larger Wirth 2019 follow-up (n=85) did not replicate the memory benefit at 12 months
  • Generally regarded as safe at supplemental doses; food-source position is reassuring

Side-by-side

Attribute Omega-3 (EPA/DHA) Spermidine
Category supplement supplement
Also known as fish oil, EPA, DHA, marine omega-3 spermidine trihydrochloride, wheat-germ-extract spermidine
Half-life (hr) 48 6
Typical dose (mg) 2000 1.2
Dosing frequency 1 to 2 times daily with food daily, typically morning with food
Routes oral oral
Onset (hr) 4 2
Peak (hr) 12 4
Molecular weight 302.45 145.25
Molecular formula C20H30O2 (EPA); C22H32O2 (DHA) C7H19N3
Mechanism Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. Induces macroautophagy via inhibition of EP300 histone acetyltransferase and activation of TFEB-mediated lysosomal biogenesis. Substrate for hypusination of eIF5A, required for translation of mitochondrial respiration proteins.
Legal status Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia OTC dietary supplement (wheat-germ extract has GRAS status in US)
WADA status allowed allowed
DEA / Rx Not scheduled OTC supplement (not scheduled)
Pregnancy Recommended at 200 to 600 mg DHA/day for fetal development Insufficient data; not routinely recommended at supplemental doses
CAS 10417-94-4 124-20-9
PubChem CID 446284 1102
Wikidata Q207688 Q411089

Safety profile

Omega-3 (EPA/DHA)

Common side effects

  • fishy aftertaste
  • eructation (fish burps)
  • mild dyspepsia
  • loose stools at high doses

Contraindications

  • fish allergy (use algal omega-3 alternative)
  • active bleeding disorders
  • scheduled surgery (discontinue 5-7 days prior)

Interactions

  • warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
  • aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
  • statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
  • antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)

Spermidine

Common side effects

  • mild GI upset (rare)
  • headache (rare)

Contraindications

  • wheat-germ allergy or celiac disease (for wheat-germ-extract products)
  • active cancer (theoretical)
  • pregnancy and lactation (insufficient data)

Interactions

  • DFMO (difluoromethylornithine): competing polyamine metabolism; do not combine without oncology guidance(moderate)

Which Should You Take?

Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Spermidine is the right call when one of the conditionals below applies.

Edge case: Half-lives differ materially (Omega-3 (EPA/DHA) ~48 hr vs Spermidine ~6 hr). Omega-3 (EPA/DHA) reaches steady state faster; Spermidine is easier to dial in if tolerability is uncertain.

Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Spermidine only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Omega-3 (EPA/DHA) and Spermidine?

Omega-3 (EPA/DHA) and Spermidine differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Omega-3 (EPA/DHA) or Spermidine?

Omega-3 (EPA/DHA) half-life is 48 hours; Spermidine half-life is 6 hours.

Can you stack Omega-3 (EPA/DHA) with Spermidine?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper